Out of 98 subjects who had participated in the 2000 JE vaccination campaign, 69 people were enrolled in the tests of 2004 and 2005 for the evaluation of long term immune response of a single dose of live attenuated SA14-14-2 JE vaccine. 89.9% of study subjects (62/69) had maintained a high level of neutralizing antibody until 2004 as their GMT was measured as 133 (Min 11, Max 2991). Forty-four subjects were still positive in 2005, 5 years after JE vaccination, and their neutralizing antibody positive rate was significantly higher than that of 69 age-sex matched unvaccinated control subjects: 63.8% (44/69) vs. 14.5% (10/69) (P<0.05). Twenty-four subjects (Group 1) who were seronegative for neutralizing antibody at the 2005 test were given a ...
SummaryObjectivesThe SA14-14-2 Japanese encephalitis (JE) live attenuated vaccine is licensed for us...
Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) i...
Background: Genotype I (GI) Japanese encephalitis virus (JEV) that replaced GIII virus has become th...
Attenuated SA14-14-2 Japanese encephalitis (JE) vaccine has been administered safely and effectively...
BACKGROUND: In July, 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis vaccine...
million children have been immunised with the SA 14-14-2 live-attenuated Japanese encephalitis (JE) ...
BACKGROUND: This study evaluated the effect of a booster vaccination of a new, live attenuated, Japa...
BackgroundThe burden of Japanese encephalitis (JE) is substantial and is arguably one of the most se...
Japanese encephalitis is the main cause of viral encephalitis in Asia. In a previous single-arm vacc...
AbstractBackgroundThe performance of live attenuated Japanese Encephalitis SA 14-14-2 vaccine (CD-JE...
The authors aimed to evaluate the safety and immunogenicity of a live attenuated SA14-14-2 Japanese ...
Objectives: We estimate the effectiveness of Japanese encephalitis (JE) SA 14-14-2 live-attenuated v...
AbstractIn a study conducted in a non-endemic area, a live attenuated Japanese encephalitis chimeric...
A new live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) has been developed based ...
Myanmar is an endemic country for the Japanese encephalitis virus (JEV), and the SA-14-14-2 live-att...
SummaryObjectivesThe SA14-14-2 Japanese encephalitis (JE) live attenuated vaccine is licensed for us...
Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) i...
Background: Genotype I (GI) Japanese encephalitis virus (JEV) that replaced GIII virus has become th...
Attenuated SA14-14-2 Japanese encephalitis (JE) vaccine has been administered safely and effectively...
BACKGROUND: In July, 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis vaccine...
million children have been immunised with the SA 14-14-2 live-attenuated Japanese encephalitis (JE) ...
BACKGROUND: This study evaluated the effect of a booster vaccination of a new, live attenuated, Japa...
BackgroundThe burden of Japanese encephalitis (JE) is substantial and is arguably one of the most se...
Japanese encephalitis is the main cause of viral encephalitis in Asia. In a previous single-arm vacc...
AbstractBackgroundThe performance of live attenuated Japanese Encephalitis SA 14-14-2 vaccine (CD-JE...
The authors aimed to evaluate the safety and immunogenicity of a live attenuated SA14-14-2 Japanese ...
Objectives: We estimate the effectiveness of Japanese encephalitis (JE) SA 14-14-2 live-attenuated v...
AbstractIn a study conducted in a non-endemic area, a live attenuated Japanese encephalitis chimeric...
A new live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) has been developed based ...
Myanmar is an endemic country for the Japanese encephalitis virus (JEV), and the SA-14-14-2 live-att...
SummaryObjectivesThe SA14-14-2 Japanese encephalitis (JE) live attenuated vaccine is licensed for us...
Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) i...
Background: Genotype I (GI) Japanese encephalitis virus (JEV) that replaced GIII virus has become th...